Counter-regulatory renin–angiotensin system in cardiovascular disease
M Paz Ocaranza, JA Riquelme, L García… - Nature Reviews …, 2020 - nature.com
The renin–angiotensin system is an important component of the cardiovascular system.
Mounting evidence suggests that the metabolic products of angiotensin I and II—initially …
Mounting evidence suggests that the metabolic products of angiotensin I and II—initially …
FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases
EJ Tillman, T Rolph - Frontiers in endocrinology, 2020 - frontiersin.org
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
Nonalcoholic fatty liver disease: an emerging driver of hypertension
Hypertension, a multifactorial disorder resulting from the interplay between genetic
predisposition and environmental risk factors, affects≈ 30% of adults. Emerging evidence …
predisposition and environmental risk factors, affects≈ 30% of adults. Emerging evidence …
Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease
OO Badmus, TD Hinds Jr, DE Stec - Current hypertension reports, 2023 - Springer
Abstract Purpose of Review Metabolic-associated fatty liver disease (MAFLD) is a condition
of fat accumulation in the liver that occurs in the majority of patients in combination with …
of fat accumulation in the liver that occurs in the majority of patients in combination with …
The FGF metabolic axis
X Li - Frontiers of Medicine, 2019 - Springer
Members of the fibroblast growth factor (FGF) family play pleiotropic roles in cellular and
metabolic homeostasis. During evolution, the ancestor FGF expands into multiple members …
metabolic homeostasis. During evolution, the ancestor FGF expands into multiple members …
AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients
A Kaufman, L Abuqayyas, WS Denney, EJ Tillman… - Cell Reports …, 2020 - cell.com
Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in
patients with metabolic diseases. However, their effects on markers of insulin sensitivity …
patients with metabolic diseases. However, their effects on markers of insulin sensitivity …
Fibroblast growth factor 21 in metabolic syndrome
M Yang, C Liu, N Jiang, Y Liu, S Luo, C Li… - Frontiers in …, 2023 - frontiersin.org
Metabolic syndrome is a complex metabolic disorder that often clinically manifests as
obesity, insulin resistance/diabetes, hyperlipidemia, and hypertension. With the …
obesity, insulin resistance/diabetes, hyperlipidemia, and hypertension. With the …
[HTML][HTML] Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate …
Objective Glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1RA) and fibroblast
growth factor-21 (FGF21) confer similar metabolic benefits. GLP-1RA induce FGF21, leading …
growth factor-21 (FGF21) confer similar metabolic benefits. GLP-1RA induce FGF21, leading …
Fibroblast growth factor 21 in heart failure
Abstract Fibroblast growth factor 21 (FGF21) is a peptide hormone involved in energy
homeostasis that protects against the development of obesity and diabetes in animal …
homeostasis that protects against the development of obesity and diabetes in animal …
The role of FGF21 in the pathogenesis of cardiovascular disease
Y Zhang, D Liu, XX Long, QC Fang, WP Jia… - Chinese Medical …, 2021 - mednexus.org
The morbidity and mortality of cardiovascular diseases (CVDs) are increasing worldwide
and seriously threaten human life and health. Fibroblast growth factor 21 (FGF21), a …
and seriously threaten human life and health. Fibroblast growth factor 21 (FGF21), a …